Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more
Windtree Therapeutics Inc (WINT) - Net Assets
Latest net assets as of September 2025: $-11.60 Million USD
Based on the latest financial reports, Windtree Therapeutics Inc (WINT) has net assets worth $-11.60 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.98 Million) and total liabilities ($27.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.60 Million |
| % of Total Assets | -72.58% |
| Annual Growth Rate | 3.58% |
| 5-Year Change | -85.63% |
| 10-Year Change | 20.93% |
| Growth Volatility | 300.75 |
Windtree Therapeutics Inc - Net Assets Trend (1995–2024)
This chart illustrates how Windtree Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Windtree Therapeutics Inc (1995–2024)
The table below shows the annual net assets of Windtree Therapeutics Inc from 1995 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $10.00 Million | +194.78% |
| 2023-12-31 | $3.39 Million | -66.13% |
| 2022-12-31 | $10.01 Million | -76.09% |
| 2021-12-31 | $41.88 Million | -39.78% |
| 2020-12-31 | $69.55 Million | -7.18% |
| 2019-12-31 | $74.94 Million | +10.01% |
| 2018-12-31 | $68.11 Million | +384.76% |
| 2017-12-31 | $-23.92 Million | +17.03% |
| 2016-12-31 | $-28.83 Million | -448.78% |
| 2015-12-31 | $8.27 Million | -56.95% |
| 2014-12-31 | $19.20 Million | -67.18% |
| 2013-12-31 | $58.50 Million | +231.39% |
| 2012-12-31 | $17.65 Million | +1296.60% |
| 2011-12-31 | $1.26 Million | -79.02% |
| 2010-12-31 | $6.03 Million | +34.30% |
| 2009-12-31 | $4.49 Million | -58.96% |
| 2008-12-31 | $10.93 Million | -71.81% |
| 2007-12-31 | $38.78 Million | +170.78% |
| 2006-12-31 | $14.32 Million | -58.89% |
| 2005-12-31 | $34.84 Million | +65.13% |
| 2004-12-31 | $21.10 Million | -13.19% |
| 2003-12-31 | $24.30 Million | +64.64% |
| 2002-12-31 | $14.76 Million | -16.24% |
| 2001-12-31 | $17.62 Million | +7.22% |
| 2000-12-31 | $16.44 Million | +428.83% |
| 1999-12-31 | $3.11 Million | -11.20% |
| 1998-12-31 | $3.50 Million | -67.59% |
| 1997-12-31 | $10.80 Million | +575.00% |
| 1996-12-31 | $1.60 Million | -55.56% |
| 1995-12-31 | $3.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Windtree Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 83981000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $305.00K | 3.05% |
| Other Components | $856.30 Million | 8566.44% |
| Total Equity | $10.00 Million | 100.00% |
Windtree Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Windtree Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Biofrontera Inc. Warrants
NASDAQ:BFRIW
|
$586.78K |
|
Capital Trust Limited
NSE:CAPTRUST
|
$586.90K |
|
Cheche Group Inc. Warrant
NASDAQ:CCGWW
|
$587.06K |
|
York Timber Holdings Ltd
JSE:YRK
|
$587.38K |
|
Joshua Gold Resources Inc
PINK:JSHG
|
$586.43K |
|
Sylla Gold Corp.
PINK:SYGCF
|
$586.29K |
|
Cartica Acquisition Corp Warrant
NASDAQ:CITEW
|
$586.20K |
|
Premier Biomedical Inc
PINK:BIEI
|
$585.78K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Windtree Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,391,000 to 9,996,000, a change of 6,605,000 (194.8%).
- Net loss of 5,487,000 reduced equity.
- Dividend payments of 657,000 reduced retained earnings.
- Share repurchases of 1,876,000 reduced equity.
- New share issuances of 5,486,000 increased equity.
- Other factors increased equity by 9,139,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.49 Million | -54.89% |
| Dividends Paid | $657.00K | -6.57% |
| Share Repurchases | $1.88 Million | -18.77% |
| Share Issuances | $5.49 Million | +54.88% |
| Other Changes | $9.14 Million | +91.43% |
| Total Change | $- | 194.78% |
Book Value vs Market Value Analysis
This analysis compares Windtree Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $0.00 | $0.02 | x |
| 1996-12-31 | $0.00 | $0.02 | x |
| 1997-12-31 | $0.00 | $0.02 | x |
| 1998-12-31 | $583333.33 | $0.02 | x |
| 1999-12-31 | $155400000.00 | $0.02 | x |
| 2000-12-31 | $498060.61 | $0.02 | x |
| 2001-12-31 | $440575000.00 | $0.02 | x |
| 2002-12-31 | $295220000.00 | $0.02 | x |
| 2003-12-31 | $347185714.29 | $0.02 | x |
| 2004-12-31 | $263712500.00 | $0.02 | x |
| 2005-12-31 | $348380000.00 | $0.02 | x |
| 2006-12-31 | $130200000.00 | $0.02 | x |
| 2007-12-31 | $277007142.86 | $0.02 | x |
| 2008-12-31 | $64311764.71 | $0.02 | x |
| 2009-12-31 | $22435000.00 | $0.02 | x |
| 2010-12-31 | $19438709.68 | $0.02 | x |
| 2011-12-31 | $2106666.67 | $0.02 | x |
| 2012-12-31 | $16974038.46 | $0.02 | x |
| 2013-12-31 | $40069178.08 | $0.02 | x |
| 2014-12-31 | $8420614.04 | $0.02 | x |
| 2015-12-31 | $3559.86 | $0.02 | x |
| 2016-12-31 | $-10389.19 | $0.02 | x |
| 2017-12-31 | $-3490.44 | $0.02 | x |
| 2018-12-31 | $2274.03 | $0.02 | x |
| 2019-12-31 | $342.86 | $0.02 | x |
| 2020-12-31 | $199936.76 | $0.02 | x |
| 2021-12-31 | $76116.83 | $0.02 | x |
| 2022-12-31 | $14302.86 | $0.02 | x |
| 2023-12-31 | $787.51 | $0.02 | x |
| 2024-12-31 | $190.10 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Windtree Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.79x
- Recent ROE (-54.89%) is above the historical average (-253.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -77.78% | -2800.00% | 0.03x | 1.11x | $-3.16 Million |
| 1996 | -143.75% | -1150.00% | 0.11x | 1.19x | $-2.46 Million |
| 1997 | -104.55% | -1314.29% | 0.06x | 1.33x | $-10.08 Million |
| 1998 | -445.71% | -15600.00% | 0.02x | 1.31x | $-15.95 Million |
| 1999 | -159.52% | -2785.39% | 0.04x | 1.49x | $-5.27 Million |
| 2000 | -66.08% | -1465.72% | 0.04x | 1.20x | $-12.50 Million |
| 2001 | -63.25% | -1002.34% | 0.06x | 1.14x | $-12.91 Million |
| 2002 | -118.17% | -978.84% | 0.08x | 1.43x | $-18.92 Million |
| 2003 | -99.91% | -2341.37% | 0.03x | 1.35x | $-26.71 Million |
| 2004 | -219.00% | -3821.59% | 0.03x | 1.78x | $-48.31 Million |
| 2005 | -169.08% | -43958.21% | 0.00x | 1.61x | $-62.39 Million |
| 2006 | -323.51% | 0.00% | 0.00x | 2.40x | $-47.77 Million |
| 2007 | -103.16% | 0.00% | 0.00x | 1.62x | $-43.88 Million |
| 2008 | -357.69% | -850.13% | 0.14x | 3.01x | $-40.20 Million |
| 2009 | -673.95% | 0.00% | 0.00x | 4.77x | $-30.69 Million |
| 2010 | -318.20% | 0.00% | 0.00x | 2.41x | $-19.78 Million |
| 2011 | -1658.62% | -3602.23% | 0.04x | 10.54x | $-21.09 Million |
| 2012 | -211.38% | -19135.90% | 0.01x | 1.70x | $-39.08 Million |
| 2013 | -77.29% | -11653.35% | 0.00x | 1.53x | $-51.07 Million |
| 2014 | -229.48% | -1554.07% | 0.06x | 2.47x | $-45.98 Million |
| 2015 | -667.43% | -5589.67% | 0.02x | 5.37x | $-56.00 Million |
| 2016 | 0.00% | -1933.89% | 0.21x | 0.00x | $-36.61 Million |
| 2017 | 0.00% | -1242.15% | 0.44x | 0.00x | $-16.05 Million |
| 2018 | -30.15% | -1148.38% | 0.01x | 1.75x | $-27.34 Million |
| 2019 | -36.67% | -13876.26% | 0.00x | 1.59x | $-34.97 Million |
| 2020 | -43.54% | 0.00% | 0.00x | 1.62x | $-37.24 Million |
| 2021 | -161.50% | 0.00% | 0.00x | 1.79x | $-71.82 Million |
| 2022 | -391.61% | 0.00% | 0.00x | 3.79x | $-40.21 Million |
| 2023 | -598.38% | 0.00% | 0.00x | 9.56x | $-20.63 Million |
| 2024 | -54.89% | 0.00% | 0.00x | 2.79x | $-6.49 Million |
Industry Comparison
This section compares Windtree Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Windtree Therapeutics Inc (WINT) | $-11.60 Million | -77.78% | N/A | $586.68K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |